Health Care Professionals


To access detailed information for Health Care Professionals, registration is required.

Ask for an account (see bottom left) or send an email to question@theravia.com or contact the Orphacol® representative in your country.

Orphacol (cholic acid) Site web éducationnel et Base de données de surveillance des patients
Orphacol (cholic acid) Educational web site and patient surveillance database
Sitio web educativo de Orphacol (cholic acid) y base de datos de vigilancia de pacientes


Orphacol (cholic acid) Site web éducationnel et Base de données de surveillance des patients
Ce site est exclusivement destiné aux professionnels de santé qui auront à diagnostiquer, initier et suivre la prise en charge médicamenteuse des patients susceptibles de présenter des erreurs congénitales de la synthèse des acides biliaires primaires dues à un déficit en 3β-hydroxy-Δ5-C27-stéroïde oxydoréductase ou en Δ4-3-oxostéroïde-5β-réductase. Il s’inscrit dans le cadre du plan de gestion des risques (PGR) d’Orphacol (cholic acid).
retour haut

Orphacol (cholic acid) Educational web site and patient surveillance database
This website is intended for health care professionals who will may diagnose, treat and monitor patients with inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency.
back up

Sitio web educativo de Orphacol (cholic acid) y base de datos de vigilancia de pacientes
Esta página web está destinada a profesionales de la salud que puedan diagnosticar, tratar y vigilar a pacientes con errores innatos en la síntesis primaria de ácidos biliares debido a la deficiencia de 3β-Hydroxi-Δ5-C27-esteroide oxidorreductasa o de Δ4-3-oxosteroide-5β-reductasa.
back up


Where can I learn more about inborn errors in primary bile acid synthesis?
More information can be found on the web site for rare diseases: Orphanet, including information on expert centres and networks.

Where can I find more information about Orphacol?
More information can be found on the EMA website: click here


This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Este medicamento está sujeto a seguimiento adicional. Esto permitirá una rápida identificación de nueva información de seguridad. Se invita a los profesionales sanitarios a notificar las sospechas de reacciones adversas.
ORPHACOL®
question@theravia.com
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not solely be used as a basis for diagnosis or treatment.
Registered for Orphacol®
Legal Mentions
ICTA PM